Eli Lilly And Co (NYSE:LLY) Shares Sold by Arthur M. Cohen & Associates LLC

Arthur M. Cohen & Associates LLC lowered its position in Eli Lilly And Co (NYSE:LLY) by 3.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 46,350 shares of the company’s stock after selling 1,830 shares during the period. Eli Lilly And Co comprises approximately 1.9% of Arthur M. Cohen & Associates LLC’s investment portfolio, making the stock its 13th biggest position. Arthur M. Cohen & Associates LLC’s holdings in Eli Lilly And Co were worth $6,092,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of LLY. West Oak Capital LLC raised its position in shares of Eli Lilly And Co by 33.7% during the 4th quarter. West Oak Capital LLC now owns 7,165 shares of the company’s stock worth $942,000 after purchasing an additional 1,805 shares during the last quarter. Diversified Trust Co acquired a new position in shares of Eli Lilly And Co during the 4th quarter worth about $743,000. Pure Financial Advisors Inc. raised its position in shares of Eli Lilly And Co by 8.1% during the 4th quarter. Pure Financial Advisors Inc. now owns 2,708 shares of the company’s stock worth $356,000 after purchasing an additional 204 shares during the last quarter. Hexavest Inc. raised its position in shares of Eli Lilly And Co by 42.1% during the 4th quarter. Hexavest Inc. now owns 354,764 shares of the company’s stock worth $46,627,000 after purchasing an additional 105,065 shares during the last quarter. Finally, Nachman Norwood & Parrott Inc raised its position in shares of Eli Lilly And Co by 4.2% during the 4th quarter. Nachman Norwood & Parrott Inc now owns 14,888 shares of the company’s stock worth $1,957,000 after purchasing an additional 600 shares during the last quarter. Institutional investors and hedge funds own 76.46% of the company’s stock.

Eli Lilly And Co stock opened at $135.92 on Friday. The firm has a 50 day simple moving average of $124.92 and a 200-day simple moving average of $114.67. Eli Lilly And Co has a 1-year low of $101.36 and a 1-year high of $137.00. The company has a debt-to-equity ratio of 4.09, a current ratio of 1.17 and a quick ratio of 0.88. The stock has a market cap of $128.38 billion, a price-to-earnings ratio of 24.49, a price-to-earnings-growth ratio of 1.75 and a beta of 0.20.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 23rd. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.43 by $0.05. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The business had revenue of $5.48 billion during the quarter, compared to analysts’ expectations of $5.50 billion. During the same quarter in the prior year, the company posted $1.39 EPS. The business’s revenue for the quarter was up 3.2% on a year-over-year basis. Equities analysts expect that Eli Lilly And Co will post 5.8 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 14th will be paid a $0.74 dividend. This is a boost from Eli Lilly And Co’s previous quarterly dividend of $0.65. The ex-dividend date of this dividend is Thursday, February 13th. This represents a $2.96 annualized dividend and a dividend yield of 2.18%. Eli Lilly And Co’s dividend payout ratio is 46.49%.

A number of analysts have commented on LLY shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $143.00 price objective on shares of Eli Lilly And Co in a report on Monday, December 2nd. UBS Group cut their price objective on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a report on Thursday, October 17th. Bank of America started coverage on shares of Eli Lilly And Co in a report on Wednesday, October 16th. They issued a “buy” rating and a $133.00 price objective for the company. Morgan Stanley upgraded shares of Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $116.00 to $150.00 in a report on Wednesday, December 18th. They noted that the move was a valuation call. Finally, Argus increased their price objective on shares of Eli Lilly And Co from $145.00 to $165.00 and gave the company a “buy” rating in a report on Monday, December 30th. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $135.67.

In related news, SVP Myles O’neill sold 25,000 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the completion of the transaction, the senior vice president now owns 40,424 shares of the company’s stock, valued at approximately $4,850,880. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Joshua L. Smiley acquired 929 shares of the stock in a transaction that occurred on Friday, October 25th. The shares were bought at an average cost of $107.59 per share, with a total value of $99,951.11. Following the transaction, the chief financial officer now directly owns 31,524 shares in the company, valued at approximately $3,391,667.16. The disclosure for this purchase can be found here. In the last three months, insiders bought 8,405 shares of company stock valued at $909,004 and sold 1,355,504 shares valued at $161,345,512. Corporate insiders own 0.11% of the company’s stock.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Penny Stocks, What You Need To Know

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.